Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Q3 Loss Narrows to $8.5M; $63.2M Cash Funds Operations Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.84
Mkt Cap
$38.207M
52W Low
$3.53
52W High
$9.12
52W Position info
8.8% above low
Off High info
58% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SCYX is trading near its 52-week low of $3.53 (8.8% above the low) on light trading volume (0.1× avg).

Summary

SCYNEXIS posted a $8.5M Q3 net loss, roughly flat year over year, with $63.2M in cash and investments that management says funds operations into 2029. The BARDA contract of up to $213.9M provides non-dilutive support for SCY-247.


Key Events · Earnings and Guidance · SCYX

  • Q3 Loss Roughly Flat Year Over Year

    Net loss was $8.5M, or $0.71 per share, versus $8.6M, or $1.38 per share, in Q3 2025. Nine-month net loss widened to $22.4M from $20.9M.

  • Cash of $63.2M, Runway Into 2029

    Cash, cash equivalents and investments totaled $63.2M at September 30, 2026, versus $56.3M at December 31, 2025. Management states capital resources fund operations for at least 12 months and into 2029.

  • R&D Spend Up on Phase 1 Programs

    R&D expense rose 14% to $6.2M in Q3, driven by a $1.2M increase for the SCY-247 IV Phase 1 study and $1.3M for the SCY-770 Phase 1 study, partly offset by $1.1M lower MARIO Phase 3 costs.

  • BARDA Contract Up to $213.9M

    The September 25, 2026 BARDA contract provides up to $213.9M in non-dilutive funding, with an $18.5M base period to advance SCY-247 into a Phase 2 study; the balance is subject to up to six options over as long as ten years.


Analysis · SCYX · Life Sciences

The quarter itself was steady — net loss of $8.5M versus $8.6M a year ago — but the balance sheet is the story. Cash and investments stood at $63.2M at September 30, down from the $71.1M reported with Q2, and management still says that funds operations into 2029. That runway is what carries the company to the SCY-770 Phase 2 proof-of-concept readout, with trial initiation guided to Q4 2026 and an interim analysis in Q4 2027. The $8.7M warrant fair-value gain that flattered the nine-month loss is non-cash and driven by share-price movement, not operations. The BARDA award of up to $213.9M ($18.5M in the base period) is non-dilutive funding that offsets SCY-247 development costs, reducing the need to raise equity for that program.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCYX was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.2M. The 52-week trading range was $3.53 to $9.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCYX - Latest Insights

SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $2.61 info
Change: -$2.57 (-50%) info
Market Cap: $25.928M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.61 info
Change: -$2.10 (-45%) info
Market Cap: $25.928M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $2.61 info
Change: -$3.85 (-60%) info
Market Cap: $25.928M info
SCYX
Aug 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.61 info
Change: -$2.66 (-50%) info
Market Cap: $25.928M info
SCYX
Aug 10, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $2.61 info
Change: -$2.55 (-49%) info
Market Cap: $25.928M info